DR. PETER RABINS – THE 36-HOUR DAY 9 25 21

DR. PETER RABINS – THE 36-HOUR DAY 9 25 21

Ever wondered why some drugs spark heated debates even before they hit the shelves? In this episode of 'American Medicine Today', Dr. Peter Rabins sheds light on the FDA-approved Alzheimer's drug, Adjuhelm, which has stirred quite a controversy. Dr. Rabins, co-author of 'The 36-Hour Day', a go-to guide for families dealing with Alzheimer's, joins hosts Kimberly Bermel, Ethan Eucher, Jeff Wagstaff, and Dr. Alfred Banati to unpack the complexities surrounding this medication.

Adjuhelm aims to remove beta amyloid protein, thought to be a precursor to Alzheimer's disease. While it reportedly clears up to 70% of this abnormal protein, many physicians are skeptical due to insufficient clinical trials. Dr. Rabins points out that the drug was only tested on individuals with very mild forms of the disease, and despite reducing the protein, it didn't improve cognitive functions.

Moreover, the medication comes with a hefty price tag—$56,000 a year—alongside additional costs for brain scans and monthly infusions. And it's not without risks; side effects include brain swelling and micro hemorrhages, making it far from a simple solution. Dr. Rabins also emphasizes the crucial role of caregivers in managing Alzheimer's, discussing practical advice from his book that addresses real-world challenges faced by families.

This episode raises essential ethical questions about the rush to approve new drugs and their impact on patients and caregivers alike. For anyone touched by Alzheimer's or interested in the ethical landscape of drug approvals, this episode offers valuable insights and heartfelt discussions.